Catalyst Pharmaceutical Partners, Inc. (CPRX)

Home > Quotes > CPRX

CPRX

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.

Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols

Symbol Lookup

Community Home
Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more!
Join Today
Already a member?

Save stocks for next time

| Sponsored

Compliance
Status

News

Price
Charts

Trade
History

Annual
Report

Earnings
Report Date

Dynamic quotes: Off

Best Bid /Ask:	$ 0.835 / $ 0.85
1 Year Target:	2.25
Today's High/Low:	$ 0.87 / $ 0.8126
Share Volume:	354,701
50 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume.	848,194
Previous Close:	$ 0.8496
52 Week High /Low:	$ 2.27 / $ 0.37
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.	34,586,274
P/E Ratio:	NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year.	NE
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS.	$ -0.13
Annualized dividend	N/A
Ex Dividend Date	N/A
Dividend Payment Date	N/A
Current Yield	0 %
Beta	1.21
NASDAQ Official Open Price NASDAQ Official Opening Price: This process identifies the NASDAQ-specific opening prices for NASDAQ-listed issues.	$ 0.84
Date of Open Price This field refers to the date the NASDAQ Official Open Price was disseminated for a given stock. It is possible that the date will not be from the current trading day; this indicates that the stock didn't trade on NASDAQ during the current trading day. The NASDAQ Official Open Price is updated only when the stock is traded on NASDAQ.	May 23, 2013
NASDAQ Official Close Price The NASDAQ® Official Closing Price (NOCP) is a process for identifying the NASDAQ market-specific closing price for NASDAQ-listed issues. The NOCP replaces the NASDAQ market-specific closing price that was based solely on the last reported NASDAQ trade. Subject to review by NASDAQ MarketWatch, the NOCP will equal the normalized price of the last trade reported to NASDAQ’s proprietary trade reporting system—Automated Confirmation Transaction ServiceSM (ACTSM—with a last sale eligible sale condition modifier as of 4:00:02 p.m., US Eastern Time. "Normalizing" the NOCP means it will be adjusted to the nearest prevailing inside quote whenever the last sale is reported away from the inside market. Market participants, data distributors and investors will be provided with the NOCP for all NASDAQ Global Select MarketSM, NASDAQ Global MarketSM and NASDAQ Capital MarketSM securities.	$ 0.8401
Date of Close Price This field refers to the date the NOCP was disseminated for a given stock. It is possible that the date will not be from the prior day; this indicates that the stock didn't trade on NASDAQ on the prior day. The NOCP is updated only when the stock is traded on NASDAQ.	May 22, 2013
Community Sentiment

Intraday Chart

5d | 1m | 6m | 12m | More Charting

Company Description (as filed with the SEC)

We are a development-stage specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting (rare) orphan neuromuscular and neurological diseases and disorders. We currently have three pharmaceutical products in development: • Firdapse™. In October 2012, we licensed the North American rights to Firdapse™, a proprietary form of amifampridine phosphate, or chemically known as 3,4-diaminopyridine phosphate, from BioMarin Pharmaceutical Inc. (BioMarin). As part of our agreements with BioMarin, we are currently taking over the sponsorship of their ongoing Phase III clinical trial evaluating Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS, a rare and sometimes fatal autoimmune disease characterized by muscle weakness. ... More ...